Navigation Links
Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
Date:9/14/2007

- FINANCIAL TABLES TO FOLLOW -

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

Three months ended June 30, Year ended June 30,

2007 2006 2007 2006

REVENUES

Royalty income $1,901,000 1,377,000 $6,853,000 $5,063,000

Technology sale

and collaboration

services 2,093,000 2,946,000 10,820,000 7,276,000

Total revenues 3,994,000 4,323,000 17,673,000 12,339,000

EXPENSES

Research and

development 7,508,000 7,944,000 26,737,000 22,808,000

Acquired in-process

research

and development -- -- -- 11,501,000

General and

administrative 1,792,000 1,225,000 6,537,000 5,968,000

Total expenses 9,300,000 9,169,000 33,274,000 40,277,000

Operating loss (5,306,000) (4,846,000) (15,601,000) (27,938,000)

Non-cash gain on

change in fair

value of warrants 980,000 -- 980,000 --

Investment income 140,000 171,000 494,000 399,000

Loss before

income tax $(4,186,000) $(4,675,000) $(14,127,000) $(27,539,000)

Provision for

income taxes -- 170,000 -- 300,000

NET LOSS $(4,186,000) $(4,845,000) $(14,127,000) $(27,839,000)

BASIC and DILUTED NET

LOSS PER SHARE $(0.13) $(0.16) $(0.47) $(0.98)

Shares used in basic

and diluted net

loss per share

calculation 32,685,615 29,546,326 30,364,114 28,490,373

SELECTED CONSOLIDATED BALANCE SHEET DATA

June 30, June 30,

2007 2006

'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2